



# BAFNA PHARMACEUTICALS LIMITED

REGD. OFFICE: "BAFNA TOWERS" 299 THAMBU CHETTY STREET, CHENNAI - 600 001, INDIA.  
PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, Email: info@bafnapharma.com, Website: www.bafnapharma.com  
CIN:L24294 TN1995PLCO30698

BPL SE CS LODR 01/2024.

To,

February 02, 2024.

Listing Department, BSE Limited, P J Towers, Dalal Street, Mumbai – 400001.	Listing Department, National Stock Exchange of India, Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400051.
Security Code: 532989 Security ID: BAFNAPHARM	Symbol: BAFNAPH Series: EQ.

Dear Sir/Madam,

**Subject: Intimation of meeting of Board of Directors – Approval of Q3 FY24 Financial Results.**

Reference: BPL SE CS PIT 44/2023 dated December 29, 2023.

-----  
We would like to bring to your notice that a meeting of Board of Directors of the Company is scheduled to be held on **Monday, February 12, 2024**, inter-alia, to consider and approve the Un-Audited Standalone Financial Results of the Company for the third quarter of FY24 ended December 31, 2023, together with the 'Limited Review Report' for the said period.

This intimation is given pursuant to Regulations 29(1) and 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

In terms of SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window to deal in the equity shares of the Company, by the designated employees, is closed since December 31, 2023, and shall remain closed up to February 14, 2024 (both days inclusive).

This intimation shall also be available on the Company's website [www.bafnapharma.com](http://www.bafnapharma.com)

Kindly take the information on record.

Thank you,

Yours faithfully,  
For Bafna Pharmaceuticals Limited,

\_\_\_\_\_  
(Vishnu V. Kuppa)  
Company Secretary & Compliance Officer.